AstraZeneca acquired ZS Pharma

AstraZeneca to acquire ZS Pharma for $90 per share.Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review, and is expected to contribute Product Sales from 2016 and benefit AstraZeneca’s return to growth strategy

AstraZeneca announced on friday, November 6th, that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ion­-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).

The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition associated with increased mortality in CKD and CHF. ZS-9 is under regulatory review by the US Food and Drug Administration with a Prescription Drug User Fee Act goal date of 26 May 2016. A submission for European Marketing Application Authorisation is planned by the end of 2015. Current estimates for global peak year sales of ZS-9 exceed $1 billion.

The acquisition continues AstraZeneca’s track record of targeted business development with a focus on three main therapy areas. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. 

AstraZeneca’s strategy focuses on reducing morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular disease, diabetes and chronic kidney disease. ZS-9 complements the company’s increasing focus on CKD and CHF, including the investigational medicine roxadustat, which is currently in Phase III development for patients with anaemia associated with CKD, as well as its leading diabetes portfolio.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said: “Hyperkalaemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure, however the risk is underappreciated and prevalence is increasing. This acquisition complements our strategic focus on Cardiovascular and Metabolic Disease by adding a potential best-in-class treatment to our portfolio of innovative medicines. We look forward to welcoming the ZS Pharma team to AstraZeneca.”

Under the terms of the agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction, or approximately $2.7 billion in aggregate transaction value.

Upon completion, ZS Pharma, which has around 200 employees across three sites in California, Texas and Colorado, will become a wholly owned subsidiary of AstraZeneca. The transaction does not impact AstraZeneca’s financial guidance for 2015. It is expected to generate Product Sales from 2016, with minimal earnings dilution over 2016 and 2017, becoming accretive to AstraZeneca’s core earnings from 2018.

Robert Alexander, Chief Executive Officer, ZS Pharma, said: “This agreement will allow us to maximize the potential of ZS-9, drawing on AstraZeneca’s long-standing expertise in developing and commercializing medicines for cardiovascular and metabolic diseases. We look forward to joining AstraZeneca and to working together to bring this important treatment for hyperkalaemia to the global market, helping to meet an important unmet medical need for patients”.

Fuente: AstraZeneca Media Centre
 

Haciendo click en cada uno de los links siguientes, 

accederán a los Contenidos de nuestros 

TALLERES DE CAPACITACIÓN IN COMPANY

"A MEDIDA"de las necesidades de su Organización,

y aplicados específicamente al Sector Salud y Farma

• Curso Taller ¿Cómo INCORPORAR y APLICAR Modelos de PENSAMIENTO ESTRATÉGICO en la Organización? 2015-2016:
• http://medinacasabella.blogspot.com.ar/2015/08/capacitacion-in-company-2015-curso.html

• Curso Taller de PLANEAMIENTO ESTRATÉGICO - Recetas Eficientes para Escenarios Turbulentos 2015-2016:
• http://medinacasabella.blogspot.com.ar/2015/08/capacitacion-in-company-2015-2016-curso.html

• Curso Taller ¿Cómo GERENCIAR EFICIENTEMENTE a partir del MANAGEMENT ESTRATÉGICO? 2015-2016:
• http://medinacasabella.blogspot.com.ar/2015/08/capacitacion-in-company-2015-2016-curso_98.html

• Curso Taller ¿Cómo GERENCIAR PROCESOS DE CAMBIO y no sufrir en el intento? 2015-2016: 
• http://medinacasabella.blogspot.com.ar/2015/08/capacitacion-in-company-2015-2016-curso_56.html

• Curso Taller de LIDERAZGO TRANSFORMACIONAL y TOMA DE DECISIONES para la Resolución de Problemas 2015-2016:
• http://medinacasabella.blogspot.com.ar/2015/08/capacitacion-in-company-2015-2016-curso_76.html

Consultas al mail: medinacasabella@gmail.com

ó al TE: +5411-3532-0510

.·. Miguel Ángel MEDINA CASABELLA, MSM, MBA, SMHS .·.
The George Washington University's Representative at LatAm Forums & Fairs since 2001
The George Washington University Medical Center's Representative for LatAm Countries since 1996
Former Academic Director and Change Management Professor, HSML Program for LatAm, GWU School of Medicine & Health Sciences (Washington DC)
CEO, MANAGEMENT SOLUTIONS GROUP LatAm
EMail: medinacasabella@gmail.com
Work Phone: ( 0054) 11 - 3532 - 0510
Mobile Phone (Domestic): ( 011 ) 15 - 4420 - 5103
Mobile Phone (Int´l): ( 0054) 911 - 4420 - 5103
Skype: medinacasabella
Twitter: https://twitter.com/medinacasabella and https://twitter.com/MSGLatAm
Linkedin: http://ar.linkedin.com/in/medinacasabella

 

MANAGEMENT SOLUTIONS GROUP LatAm ©
(medinacasabella@gmail.com; +5411-3532-0510)
is an Interdisciplinary Consulting Firm focused on:

Multicultural, Transcultural, Organizational & Competitive Strategy,

Strategic Management,
Change Management
Strategic Marketing,
Investments,
Education Management & Training

for Latin American (LatAm) Sectors:

a) Health, Pharma & Biotech,
b) Industrial & Services Companies,
c) Universities & Training Centers,
d) Governments, NGOs & NPOs.